ReviewInternational journal of general medicine2015
Managing comorbidities in idiopathic pulmonary fibrosis.
Review in International journal of general medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- Comorbidities' Effect on IPF: Pathogenesis and Management.Biomedicines · 2025Review
- Trends and regional variations in chronic ischemic heart disease and lung cancer-related mortality among American adults: Insights from retrospective CDC wonder analysis.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Mortality-related risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Journal of thoracic disease · 2024Article
- Review
- The Impact of Chronic Comorbidities on Outcomes in Acute Exacerbations of Idiopathic Pulmonary Fibrosis.Life (Basel, Switzerland) · 2024Article
- Article
- Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management.Respiratory research · 2021Review
- Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment - a German claims data analysis.Respiratory research · 2020Article
- Pulmonary Fibrosis among World Trade Center Responders: Results from the WTC Health Registry Cohort.International journal of environmental research and public health · 2019Article
- Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.Respiratory research · 2018Observational
- Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis.Respiratory research · 2018Article
- Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Idiopathic pulmonary fibrosis: pathogenesis and management.Respiratory research · 2018Review
- Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2017Review
- Recent advances in managing idiopathic pulmonary fibrosis.F1000Research · 2017Review
- A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival.Respiratory medicine · 2016Article
- MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.PloS one · 2016Article
- Respiratory Pathology and Cardiovascular Diseases: A Scoping Review.Open respiratory archivesArticle
- Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases. IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases. We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning. Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients. Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.